Galectin-3 in heart failure with preserved ejection fraction. A RELAX trial substudy (Phosphodiesterase-5 Inhibition to Improve Clinical Status and Exercise Capacity in Diastolic Heart Failure).

[1]  M. Pencina,et al.  Charting a roadmap for heart failure biomarker studies. , 2014, JACC. Heart failure.

[2]  A. Dick,et al.  Local expression of myocardial galectin-3 does not correlate with its serum levels in patients undergoing heart transplantation. , 2013, Annals of transplantation.

[3]  W. Paulus,et al.  A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. , 2013, Journal of the American College of Cardiology.

[4]  G. Felker,et al.  Surfing the biomarker tsunami at JACC: heart failure. , 2013, JACC. Heart failure.

[5]  J. Cohn,et al.  Baseline and serial measurements of galectin‐3 in patients with heart failure: relationship to prognosis and effect of treatment with valsartan in the Val‐HeFT , 2013, European journal of heart failure.

[6]  Manesh R. Patel,et al.  Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. , 2013, JAMA.

[7]  D. J. Veldhuisen,et al.  Prognostic Value of Changes in Galectin-3 Levels Over Time in Patients With Heart Failure: Data From CORONA and COACH , 2013, Circulation. Heart failure.

[8]  M. Morshuis,et al.  The biomarker plasma galectin-3 in advanced heart failure and survival with mechanical circulatory support devices. , 2013, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[9]  Bertram Pitt,et al.  Genetic and Pharmacological Inhibition of Galectin-3 Prevents Cardiac Remodeling by Interfering With Myocardial Fibrogenesis , 2013, Circulation. Heart failure.

[10]  R. D. de Boer,et al.  Galectin-3 Mediates Aldosterone-Induced Vascular Fibrosis , 2013, Arteriosclerosis, thrombosis, and vascular biology.

[11]  D. Levy,et al.  Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community. , 2012, Journal of the American College of Cardiology.

[12]  C. Liang,et al.  Relationship of Plasma Galectin-3 to Renal Function in Patients With Heart Failure: Effects of Clinical Status, Pathophysiology of Heart Failure, and Presence or Absence of Heart Failure , 2012, Journal of the American Heart Association.

[13]  E. Braunwald,et al.  PhosphdiesteRasE-5 Inhibition to Improve CLinical Status and EXercise Capacity in Diastolic Heart Failure (RELAX) trial: rationale and design. , 2012, Circulation. Heart failure.

[14]  J. McMurray,et al.  Galectin-3 predicts response to statin therapy in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). , 2012, European heart journal.

[15]  P. Harst,et al.  The fibrosis marker galectin‐3 and outcome in the general population , 2012, Journal of internal medicine.

[16]  B. Borlaug,et al.  Letter by Forfia and Borlaug regarding article, "Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study". , 2012, Circulation.

[17]  J. Cleland,et al.  Association of galectin‐3 and fibrosis markers with long‐term cardiovascular outcomes in patients with heart failure, left ventricular dysfunction, and dyssynchrony: insights from the CARE‐HF (Cardiac Resynchronization in Heart Failure) trial , 2012, European journal of heart failure.

[18]  I. Piña,et al.  Galectin-3 in Ambulatory Patients With Heart Failure: Results From the HF-ACTION Study , 2012, Circulation. Heart failure.

[19]  I. Piña,et al.  Galectin-3 in Ambulatory Patients With Heart FailureClinical Perspective , 2012 .

[20]  P. Muntendam,et al.  Galectin-3 in heart failure: high levels are associated with all-cause mortality. , 2011, International journal of cardiology.

[21]  James D. Thomas,et al.  Usefulness of plasma galectin-3 levels in systolic heart failure to predict renal insufficiency and survival. , 2011, The American journal of cardiology.

[22]  Hans L Hillege,et al.  Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction , 2010, Annals of medicine.

[23]  R. Arena,et al.  Pulmonary Hypertension in Heart Failure With Preserved Ejection Fraction: A Target of Phosphodiesterase-5 Inhibition in a 1-Year Study , 2009, Circulation.

[24]  M. Picard,et al.  Galectin‐3, cardiac structure and function, and long‐term mortality in patients with acutely decompensated heart failure , 2010, European journal of heart failure.

[25]  D. Lok,et al.  Prognostic value of galectin-3, a novel marker of fibrosis , 2010, Clinical Research in Cardiology.

[26]  J. McMurray,et al.  Plasma concentration of amino-terminal pro-brain natriuretic peptide in chronic heart failure: prediction of cardiovascular events and interaction with the effects of rosuvastatin: a report from CORONA (Controlled Rosuvastatin Multinational Trial in Heart Failure). , 2009, Journal of the American College of Cardiology.

[27]  D. J. Veldhuisen,et al.  Galectin‐3: a novel mediator of heart failure development and progression , 2009, European journal of heart failure.

[28]  O. Carretero,et al.  N-acetyl-seryl-aspartyl-lysyl-proline prevents cardiac remodeling and dysfunction induced by galectin-3, a mammalian adhesion/growth-regulatory lectin. , 2009, American journal of physiology. Heart and circulatory physiology.

[29]  R. Körfer,et al.  Plasma biomarkers of myocardial fibrosis and remodeling in terminal heart failure patients supported by mechanical circulatory support devices. , 2008, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[30]  R. Garrick,et al.  Estimating GFR Using Serum Cystatin C Alone and in Combination With Serum Creatinine: A Pooled Analysis of 3,418 Individuals With CKD , 2008 .

[31]  P. Ellinor,et al.  Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure. , 2006, Journal of the American College of Cardiology.

[32]  V. Roger,et al.  Trends in prevalence and outcome of heart failure with preserved ejection fraction. , 2006, The New England journal of medicine.

[33]  Yigal M. Pinto,et al.  Galectin-3 Marks Activated Macrophages in Failure-Prone Hypertrophied Hearts and Contributes to Cardiac Dysfunction , 2004, Circulation.

[34]  R. Duisters,et al.  Thrombospondin-2 Is Essential for Myocardial Matrix Integrity: Increased Expression Identifies Failure-Prone Cardiac Hypertrophy , 2004, Circulation research.